The monoclonal antibody ofatumumab appears to be more effective in achieving a disease-free state in relapsing-remitting multiple sclerosis (RRMS) than the immunomodulatory drug teriflunomide, across ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will impact their patients. Dr ...

According to recently published research, vitamins B12 and B9 can lower levels of homocysteine, improve anemia status, and boost physical health in patients with relapsing remitting multiple sclerosis ...

Five separate mediation analyses found that adaptive coping had a significant association with each PWB subscale and self-efficacy. After controlling for self-efficacy, there remained separate ...

While autologous hematopoietic stem cell transplantation (aHSCT) has shown promise as a one-time treatment option for relapsing-remitting multiple sclerosis (RRMS), it’s still unclear what role aHSCT ...

I really don't know when I transitioned from relapsing-remitting MS (RRMS) to secondary progressive MS (SPMS). It was so gradual. I was still walking when I was diagnosed in 1994. Then I started using ...

Before you switch RRMS medications, notify those on your healthcare team, including doctors, neurologists, and other specialists you might see. Let your family know, too, and consider seeking support ...

A recent prospective phase 2 study sought to investigate autologous hematopoietic stem cell transplantation as a therapeutic intervention in multiple sclerosis (MS). A recent prospective phase 2 study ...

Please provide your email address to receive an email when new articles are posted on . Treatment for relapsing-remitting MS improved in a “clinically meaningful” way between 2010 and 2018, in part ...

Relapsing-remitting multiple sclerosis (RRMS) is the most common form of multiple sclerosis (MS). You may have periods when symptoms either don’t progress or don’t occur at all (remission) followed by ...

Please provide your email address to receive an email when new articles are posted on . Patients with secondary progressive MS on disease-modifying treatments often are clinically misclassified as ...